ICICI Pru Healthcare Fund
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Growthvine rating: 5/5 — ranked #4 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹42.21 (as of 2026-10-01) |
|---|
| AUM | ₹6,996 Cr |
|---|
| Expense ratio | 1.54% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dharmesh Kakkad |
|---|
| Exit load | 1% for redemption within 15 days |
|---|
Performance & risk
| 5-year annualised return | 14.56% |
|---|
| Sharpe ratio | 1.01 |
|---|
| Standard deviation | 16.12% |
|---|
| Max drawdown | −20.72% |
|---|
| Alpha | 0.21 |
|---|
| Beta | 0.96 |
|---|
Over 5 years, captured 95.1% of NIFTY Pharma's upside and 83.6% of its downside.
Market cap allocation
| Large cap | 24.1% |
|---|
| Mid cap | 31.5% |
|---|
| Small cap | 44.4% |
|---|
Concentration
| Top 5 holdings | 36.4% |
|---|
| Top 10 holdings | 57.4% |
|---|
| Total holdings | 35 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 12.3%
- Dr. Reddys Laboratories Ltd. — 8.3%
- Cipla Ltd. — 5.8%
- Mankind Pharma Limited — 5.2%
- Alkem Laboratories Limited — 4.9%
- Divis Laboratories Ltd. — 4.8%
- TREPS — 4.8%
- Biocon Ltd. — 4.7%
- Medplus Health Services Limited — 4.2%
- Cohance Lifesciences Limited — 4.1%
Top sectors
- Pharma & Biotech — 70.7%
- Healthcare — 16.6%
- Retail — 5.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 6.0% | Q2 | #24 of 76 |
| 2025 | −0.8% | Q3 | #37 of 69 |
| 2024 | 48.1% | Q1 (Top) | #2 of 58 |
| 2023 | 41.3% | Q2 | #15 of 48 |
| 2022 | −8.5% | Q4 (Bottom) | #36 of 46 |